Sotorasib, a specific and irreversible KRASG12C inhibitor, has demonstrated clinical activity as monotherapy in KRAS p.G12C-mutated solid tumors. Genomic alterations of receptor tyrosine kinase (RTK)
were identified as a common putative resistance mechanism to sotorasib in the CodeBreaK100
Ph1/2 trial, highlighting the potential role for combining sotorasib with upstream
RTK signaling inhibitors. In mouse xenograft models, combining sotorasib with a SHP2
inhibitor (SHP2i) impaired RTK signaling to RAS and enhanced anti-tumor efficacy.
Herein, we report the first safety and efficacy data for sotorasib combined with RMC-4630,
a small molecule SHP2i.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Thoracic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
